参考文献/References:
[1]
[2] Kirchhof P,Purmah Y,Verma A. Oral anticoagulation after catheter ablation of atrial fibrillation:caught in the attribution trap?[J]. Eur Heart J,2015,36(5):267-269.
[3] Karasoy D,Gislason GH,Hansen J,et al. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding:long-term follow-up in nationwide cohort of Denmark[J]. Eur Heart J,2015,36(5):307-314.
[4] Go AS,Reynolds K,Yang J,et al. Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation:The KP-RHYTHM Study[J]. JAMA Cardiol,2018,3(7):601-608.
[5] Clarnette JA,Brooks AG,Mahajan R,et al. Outcomes of persistent and long-standing persistent atrial fibrillation ablation:a systematic review and meta-analysis[J]. Europace,2018,20(FI_3):f366-f376.
[6] Kim TH,Yang PS,Yu HT,et al. Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation:nationwide data covering the entire Korean population[J].Eur Heart J,2019,40(10):809-819.
[7] Patti G,Cavallari I,Andreotti F,et al. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs[J]. Nat Rev Cardiol,2019,16(2):113-130.
[8] Gu X,Li Y,Chen S,et al. Association of lipids with ischemic and hemorrhagic stroke: a prospective cohort study among 267500 Chinese[J]. Stroke,2019,50(12):3376-3384.
[9] Calenda BW,Fuster V,Halperin JL,et al. Stroke risk assessment in atrial fibrillation:risk factors and markers of atrial myopathy[J]. Nat Rev Cardiol,2016,13(9):549-559.
[10] Goette A,Kalman JM,Aguinaga L,et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies:definition,characterization,and clinical implication[J]. Europace,2016,18(10):1455-1490.
[11] Bisbal F,Baranchuk A,Braunwald E,et al. Atrial failure as a clinical entity:JACC review topic of the week[J]. J Am Coll Cardiol,2020,75(2):222-232.
[12] Qin D,Mansour MC,Ruskin JN,et al. Atrial fibrillation-mediated cardiomyopathy[J]. Circ Arrhythm Electrophysiol,2019,12(12):e7809.
[13] Inoue YY,Alissa A,Khurram IM,et al. Quantitative tissue-tracking cardiac magnetic resonance(CMR) of left atrial deformation and the risk of stroke in patients with atrial fibrillation[J]. J Am Heart Assoc,2015,4(4):e001844.
[14] Huisman MV,Rothman KJ,Paquette M,et al. The changing landscape for stroke?prevention in af: findings from the GLORIA-AF registry phase 2[J]. J Am Coll Cardiol,2017,69(7):777-785.
[15] 史展,孙雪荣,田颖,等. 心房颤动患者口服抗凝药物依从性的研究进展[J]. 心血管病学进展,2020,41(1):18-22.
[16] Wang ZZ,Du X,Wang W,et al. Long-term persistence of newly initiated warfarin therapy in Chinese patients with nonvalvular atrial fibrillation[J]. Circ Cardiovasc Qual Outcomes,2016,9(4):380-387.
[17] Andrade JG,Champagne J,Dubuc M,et al. Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a randomized clinical trial[J]. Circulation,2019,140(22):1779-1788.
[18] Chao TF,Liao JN,Tuan TC,et al. Incident co-morbidities in patients with atrial fibrillation initially with a CHA2DS2-VASc score of 0 (males) or 1 (females): implications for reassessment of stroke risk in initially ’low-risk’ patients[J]. Thromb Haemost,2019,119(7):1162-1170.
[19] Renda G,Ricci F,Patti G,et al. CHA2DS2VASc score and adverse outcomes in middle-aged individuals without atrial fibrillation[J]. Eur J Prev Cardiol,2019,26(18):1987-1997.
[20] Xing Y,Sun Y,Li H,et al. CHA2DS2-VASc score as a predictor of long-term cardiac outcomes in elderly patients with or without atrial fibrillation[J]. Clin Interv Aging,2018,13:497-504.
[21] Senoo K,Lane DA,Lip GY. Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population:a modeling analysis[J]. Int J Cardiol,2015,181:247-254.
[22] Qi Z,Chen H,Wen Z,et al. Relation of low-density lipoprotein cholesterol to ischemic stroke in patients with nonvalvular atrial fibrillation[J]. Am J Cardiol,2017,119(8):1224-1228.
[23] Vafaie M,Giannitsis E,Mueller-Hennessen M,et al. High-sensitivity cardiac troponin T as an independent predictor of stroke in patients admitted to an emergency department with atrial fibrillation[J]. PLoS One,2019,14(2):e212278.
[24] Cresti A,García-Fernández MA,Sievert H,et al. Prevalence of extra-appendage thrombosis in non-valvular atrial fibrillation and atrial flutter in patients undergoing cardioversion:a large transoesophageal echo study[J]. EuroIntervention,2019,15(3):e225-e230.
[25] Hwang SH,Roh SY,Shim J,et al. Atrial fibrillation: relationship between left atrial pressure and left atrial appendage emptying determined with velocity-encoded cardiac mr imaging[J]. Radiology,2017,284(2):381-389.
[26] Hamatani Y,Ogawa H,Takabayashi K,et al. Left atrial enlargement is an independent predictor of stroke and systemic embolism in patients with non-valvular atrial fibrillation[J]. Sci Rep,2016,6:31042.
[27] Lim HS,Hocini M,Dubois R,et al. Complexity and distribution of drivers?in?relation to duration of persistent?atrial?fibrillation[J]. J Am Coll Cardiol,2017,69(10):1257-1269.
[28] Romero J,Michaud GF,Avendano R,et al. Benefit of left atrial appendage electrical isolation for persistent and long-standing persistent atrial fibrillation:a systematic review and meta-analysis[J]. Europace,2018,20(8):1268-1278.
[29] Di Biase L,Mohanty S,Trivedi C,et al. Stroke risk in patients with atrial fibrillation undergoing electrical isolation of the left?atrial?appendage[J]. J Am Coll Cardiol,2019,74(8):1019-1028.
[30] Kim YG,Shim J,Oh SK,et al. Electrical isolation of the left atrial appendage increases the risk of ischemic stroke and transient ischemic attack regardless of postisolation flow velocity[J]. Heart Rhythm,2018,15(12):1746-1753.
[31] Gadiyaram VK,Mohanty S,Gianni C,et al. Thromboembolic events and need for anticoagulation therapy following left atrial appendage occlusion in patients with electrical isolation of the appendage[J]. J Cardiovasc Electrophysiol,2019,30(4):511-516.
[32] Halcox JPJ,Wareham K,Cardew A,et al. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study[J]. Circulation,2017,136(19):1784-1794.
[33] Bonomi AG,Schipper F,Eerik?inen LM,et al. Atrial fibrillation detection using a novel cardiac ambulatory monitor based on photo-plethysmography at the wrist[J]. J Am Heart Assoc,2018,7(15):e009351.
[34] Voskoboinik A,Kalman JM,de Silva A,et al. Alcohol abstinence in drinkers with atrial fibrillation[J]. N Engl J Med,2020,382(1):20-28.
[35]Kamel H,Merkler AE,Iadecola C,et al. Tailoring the approach to embolic stroke of undetermined source:a review[J].JAMA Neurol,2019,76(7):855-861.
[36] Paciaroni M,Agnelli G,Caso V,et al. Causes and risk factors of cerebral ischemic events in patients with atrial fibrillation treated with non-vitamin k antagonist oral anticoagulants for stroke prevention[J]. Stroke,2019,50(8):2168-2174.
[37] Diener HC,Sacco RL,Easton JD,et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source[J]. N Engl J Med,2019,380(20):1906-1917.
[38] Capodanno D,Huber K,Mehran R,et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing?PCI: JACC state-of-the-art review[J]. J Am Coll Cardiol,2019,74(1):83-99.
[39] Matsumura-Nakano Y,Shizuta S,Komasa A,et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation[J]. Circulation,2019,139(5):604-616.
[40] Connolly SJ,Eikelboom JW,Bosch J,et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease:an international,randomised,double-blind,placebo-controlled trial[J]. Lancet,2018,391(10117):205-218.
[41] Perera KS,Ng K,Nayar S,et al. Association between low-dose rivaroxaban with or without aspirin and ischemic stroke subtypes: a secondary analysis of the COMPASS trial[J]. JAMA Neurol,2020,77(1):43-48.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(1):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(1):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(1):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[11]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(1):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[12]赵磊 梁兆光.导管消融术后心房颤动复发的危险因素及预防[J].心血管病学进展,2019,(5):766.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.025]
ZHAO LeiLIANG Zhaoguang.Risk Factors and Prevention of Atrial Fibrillation Recurrence after Catheterablation[J].Advances in Cardiovascular Diseases,2019,(1):766.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.025]
[13]辛小宇 梁兆光.心房颤动导管消融围术期抗凝治疗研究进展[J].心血管病学进展,2020,(8):809.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.007]
XIN XiaoyuLIANG Zhaoguang.Perioperative Anticoagulation for Atrial Fibrillation Catheter Ablation[J].Advances in Cardiovascular Diseases,2020,(1):809.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.007]
[14]赵灿 吴永全.基于环肺静脉隔离的房颤导管消融策略选择治疗进展[J].心血管病学进展,2020,(12):1234.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.003]
ZHAO Can,WU Yongquan.Catheter Ablation Strategies for Atrial Fibrillation Based on Circumferential Pulmonary Vein Isolation[J].Advances in Cardiovascular Diseases,2020,(1):1234.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.003]
[15]刘玉辉 王盼盼 陈椿.心房颤动性心肌病临床研究进展[J].心血管病学进展,2020,(12):1238.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.004]
LIU Yuhui,WANG Panpan,CHEN Chun.Atrial Fibrillation-induced Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(1):1238.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.004]
[16]那丞 黄织春.干预自主神经对心房颤动影响的研究进展[J].心血管病学进展,2021,(1):30.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
NA Cheng,HUANG Zhichun.Effect of Autonomic Nerve Intervention on Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(1):30.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[17]徐尧 蔡衡 李洪仕.心房颤动合并心力衰竭的导管消融治疗[J].心血管病学进展,2021,(4):322.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.009]
XU Yao,CAI Heng,LI Hongshi.Role of Radiofrequency Ablation in Patients with Atrial Fibrillation and Heart Failure[J].Advances in Cardiovascular Diseases,2021,(1):322.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.009]
[18]袁明 谢瑞芹.导管消融对心房颤动患者生活质量影响的研究进展[J].心血管病学进展,2021,(10):884.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.005]
YUAN MingXIE Ruiqin.Effect of Catheter Ablation on Quality of Life in patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(1):884.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.005]
[19]邹永伟 胡小恋.左房低电压与心房颤动相关性的研究进展[J].心血管病学进展,2022,(3):211.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
ZHOU Yongwei,H U Xiaolian.The Correlation Between Left Atrial Low-Voltage Area and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(1):211.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[20]李珂 赵海娟 赵耀 黄松群 郭志福.肥厚型心肌病合并心房颤动的导管消融[J].心血管病学进展,2022,(5):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]
LI Ke,ZHAO Haijuan,ZHAO Yao,et al.Catheter Ablation of Hypertrophic Cardiomyopathy with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(1):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]